TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
about
Cytotoxic and targeted therapy for hereditary cancersTargeted Therapies in Triple-Negative Breast CancerLiver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the LiteratureTriple negative breast cancer: looking for the missing link between biology and treatmentsCIViC databaseIs it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage ResponsPhase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast CancerPhase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriersNovel therapeutic strategies in the treatment of triple-negative breast cancer.Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast CancerA high frequency of BRCA mutations in young black women with breast cancer residing in Florida.Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialRandomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancerTriple-negative breast cancer: treatment challenges and solutions.Development and clinical application of an integrative genomic approach to personalized cancer therapyA Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast CancerVinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane TreatmentInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort.Advances in the recognition and management of hereditary cancer.Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.Advances in PARP inhibitors for the treatment of breast cancer.Evolving treatment landscape for early and advanced pancreatic cancer.Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.Molecular trail for the anticancer behavior of a novel copper carbohydrazone complex in BRCA1 mutated breast cancer.Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.News on the medical treatment of young women with early-stage HER2-negative breast cancer.ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells.Biology and Management of Patients With Triple-Negative Breast Cancer.Long noncoding RNAs (lncRNAs) in triple negative breast cancer.Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.
P2860
Q26739366-7471E647-F95A-4FDE-B9E4-5BE2B070348DQ26777736-6225475E-E8FA-496A-8713-2BAD612E392CQ26779880-A2F51C22-1F50-4F6C-90B2-A6C8FFFA6D16Q26783122-1A02B9DE-CC0B-4CB1-9E09-45A53C0EC634Q27612411-F63F1971-6317-443A-9E40-262E7DBD06ADQ28073673-87C15F9F-BC90-4BD5-9BEB-DC8AB9E30DC4Q30253017-714822DB-B4E5-41FF-AB19-71E8A66867C9Q33429434-C122E501-D9E6-47D1-B71F-6CDAEAF7EAE0Q33440778-65BAC73C-73DA-4E7F-B738-22EC5DAFA558Q33441772-4A85BA59-0D4D-44EE-A454-5606BD23C049Q33591876-F30E5411-FBFA-47FA-BD5F-37C1B647558FQ33769821-25192DDE-DDAE-4FB4-9206-C4D452B21D65Q33823472-DC1ABC60-349B-4845-849E-4158EF5206DDQ33887682-B9FE4A7B-6F3C-4A8C-9478-BE9EE2AAC4DBQ34547261-A52C4237-E96C-4EF9-A5FB-2C20813361CFQ35845089-057734DF-8FDB-4D41-BD1C-6EAE7182CE8BQ36224769-186654F6-4DC3-4E23-A8AA-FEE3AD2FA2C3Q36338690-1D196FDF-3C87-4C68-B4FE-CB78A487328BQ36379813-5831C02F-2C00-4FB3-846B-0034184FA579Q36880037-D76AC6D2-F5F3-429B-962C-0C6305017D07Q36940085-C7283D2D-EAF5-4DC9-8032-0BD58E2D497AQ36954557-88132920-D9E7-4AD8-A0F4-7FAACCA0A1E7Q37146398-1C4C8A6A-8FE2-44E4-A971-8A0E099DB240Q37176391-F7D7FCA4-BA2D-4840-AA03-145822CEF844Q37179254-E3BC7DC8-0DFB-4A19-BBAE-3E9CEC7700B2Q37630473-F5DF5BE5-4020-4EA6-A8D8-C46CB4938B5AQ37693410-A87B350A-1291-4719-92F4-A5FE2A761B20Q38375045-A9110D81-7A70-43A7-ADF6-964252200C5BQ38375607-B3BD0B17-06CC-491A-B41D-FCA07652C52BQ38612128-5AD25D18-8135-4DC3-A068-4EEAECD22FA1Q38624806-9F2B5C60-10E8-4CC3-BEC0-C193DA00B4B3Q38641240-58AF7594-FEE0-4922-8B56-3082D5668C47Q38722992-01CC39D8-1669-40BF-A61C-A805DF9DE46CQ38806371-3DD9CF46-72A9-473B-ACA4-04DE193762C2Q38811820-2CEE0745-8825-4875-B492-8F6142C06447Q38870541-B28CDB23-CB4E-4D73-9E2A-3F1419656715Q38872046-297070D2-4E81-4A03-ABC4-38618B56EE48Q38893074-C88F132F-96B4-4BC4-8C52-F5887D5286A3Q39110866-7B85D98E-0417-44A1-9F12-BE14ED503F82Q39113994-3D0F197E-65F6-4D97-9FF2-AAF38407008C
P2860
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
TBCRC009: A Multicenter Phase ...... Triple-Negative Breast Cancer
@ast
TBCRC009: A Multicenter Phase ...... Triple-Negative Breast Cancer
@en
TBCRC009: A Multicenter Phase ...... Triple-Negative Breast Cancer.
@nl
type
label
TBCRC009: A Multicenter Phase ...... Triple-Negative Breast Cancer
@ast
TBCRC009: A Multicenter Phase ...... Triple-Negative Breast Cancer
@en
TBCRC009: A Multicenter Phase ...... Triple-Negative Breast Cancer.
@nl
altLabel
TBCRC009: A Multicenter Phase ...... Triple-Negative Breast Cancer
@en
prefLabel
TBCRC009: A Multicenter Phase ...... Triple-Negative Breast Cancer
@ast
TBCRC009: A Multicenter Phase ...... Triple-Negative Breast Cancer
@en
TBCRC009: A Multicenter Phase ...... Triple-Negative Breast Cancer.
@nl
P2093
P2860
P921
P3181
P356
P1476
TBCRC009: A Multicenter Phase ...... Triple-Negative Breast Cancer
@en
P2093
Anne-Renee Hartman
Darrel R Borger
Dianne M Finkelstein
Eric P Winer
Erica L Mayer
Hope S Rugo
Judy E Garber
Karen J Krag
Kirsten M Timms
P2860
P304
P3181
P356
10.1200/JCO.2014.57.6660
P407
P577
2015-06-10T00:00:00Z